Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Microlyse targets VWF and clears microvascular thrombosis

Feb. 23, 2022

New coagulation factor XIa inhibitors synthesized at Janssen Pharmaceutica

Feb. 18, 2022

HMB-001 bispecific antibody shows promise for treating Glanzmann thrombasthenia

Feb. 15, 2022

Janssen Pharmaceutica presents new factor XIa inhibitors

Feb. 14, 2022

Heterozygous variants in the CD36 gene linked to bleeding phenotypes

Feb. 8, 2022

A microbiota-macrophage-iron axis regulates hematopoietic stem cell fate decisions under stress

Feb. 3, 2022

HMGB1 restricts EPO signaling, contributing to anemia of inflammation

Feb. 2, 2022

MAP3K7 modulation to treat MDS-associated anemia

Jan. 10, 2022

Hematologic

Jan. 1, 2022

Emendo Biotherapeutics develops CRISPR-based ex-vivo gene editing strategy for ELANE neutropenia

Dec. 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...